nodes	percent_of_prediction	percent_of_DWPC	metapath
Aclidinium—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0442	0.054	CbGpPWpGaD
Aclidinium—CHRM4—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0208	0.0253	CbGpPWpGaD
Aclidinium—CHRM5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0199	0.0243	CbGpPWpGaD
Aclidinium—CHRM4—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0177	0.0216	CbGpPWpGaD
Aclidinium—CHRM4—nervous system—Gilles de la Tourette syndrome	0.0176	0.0976	CbGeAlD
Aclidinium—CHRM4—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0172	0.021	CbGpPWpGaD
Aclidinium—CHRM4—central nervous system—Gilles de la Tourette syndrome	0.017	0.0939	CbGeAlD
Aclidinium—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0169	0.0207	CbGpPWpGaD
Aclidinium—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0165	0.0201	CbGpPWpGaD
Aclidinium—CHRM4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.016	0.0195	CbGpPWpGaD
Aclidinium—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0153	0.0187	CbGpPWpGaD
Aclidinium—CHRM4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0149	0.0182	CbGpPWpGaD
Aclidinium—CHRM4—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0144	0.0176	CbGpPWpGaD
Aclidinium—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0142	0.0174	CbGpPWpGaD
Aclidinium—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.014	0.0171	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0139	0.017	CbGpPWpGaD
Aclidinium—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0138	0.0169	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0138	0.0169	CbGpPWpGaD
Aclidinium—CHRM5—nervous system—Gilles de la Tourette syndrome	0.0138	0.0763	CbGeAlD
Aclidinium—CHRM4—brain—Gilles de la Tourette syndrome	0.0135	0.0746	CbGeAlD
Aclidinium—CHRM4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0135	0.0164	CbGpPWpGaD
Aclidinium—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.0133	0.0734	CbGeAlD
Aclidinium—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0129	0.0157	CbGpPWpGaD
Aclidinium—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0119	0.0146	CbGpPWpGaD
Aclidinium—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0119	0.0145	CbGpPWpGaD
Aclidinium—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0118	0.0144	CbGpPWpGaD
Aclidinium—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0116	0.0141	CbGpPWpGaD
Aclidinium—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0115	0.0141	CbGpPWpGaD
Aclidinium—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0114	0.014	CbGpPWpGaD
Aclidinium—CHRM4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0112	0.0137	CbGpPWpGaD
Aclidinium—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0108	0.0132	CbGpPWpGaD
Aclidinium—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0108	0.0131	CbGpPWpGaD
Aclidinium—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0107	0.0131	CbGpPWpGaD
Aclidinium—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0107	0.013	CbGpPWpGaD
Aclidinium—CHRM5—brain—Gilles de la Tourette syndrome	0.0105	0.0583	CbGeAlD
Aclidinium—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.01	0.0122	CbGpPWpGaD
Aclidinium—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.01	0.0122	CbGpPWpGaD
Aclidinium—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0099	0.0121	CbGpPWpGaD
Aclidinium—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00974	0.0119	CbGpPWpGaD
Aclidinium—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00971	0.0118	CbGpPWpGaD
Aclidinium—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00961	0.0117	CbGpPWpGaD
Aclidinium—CHRM2—nervous system—Gilles de la Tourette syndrome	0.00946	0.0523	CbGeAlD
Aclidinium—CHRM4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00942	0.0115	CbGpPWpGaD
Aclidinium—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.00911	0.0504	CbGeAlD
Aclidinium—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00907	0.0111	CbGpPWpGaD
Aclidinium—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00904	0.011	CbGpPWpGaD
Aclidinium—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00902	0.011	CbGpPWpGaD
Aclidinium—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00896	0.0109	CbGpPWpGaD
Aclidinium—CHRM1—nervous system—Gilles de la Tourette syndrome	0.00861	0.0476	CbGeAlD
Aclidinium—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.00829	0.0459	CbGeAlD
Aclidinium—CHRM3—nervous system—Gilles de la Tourette syndrome	0.00771	0.0426	CbGeAlD
Aclidinium—BCHE—midbrain—Gilles de la Tourette syndrome	0.00765	0.0423	CbGeAlD
Aclidinium—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00756	0.00923	CbGpPWpGaD
Aclidinium—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00753	0.0092	CbGpPWpGaD
Aclidinium—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00746	0.00911	CbGpPWpGaD
Aclidinium—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.00742	0.041	CbGeAlD
Aclidinium—CHRM2—brain—Gilles de la Tourette syndrome	0.00723	0.04	CbGeAlD
Aclidinium—CHRM1—brain—Gilles de la Tourette syndrome	0.00658	0.0364	CbGeAlD
Aclidinium—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00635	0.00776	CbGpPWpGaD
Aclidinium—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00633	0.00773	CbGpPWpGaD
Aclidinium—BCHE—nervous system—Gilles de la Tourette syndrome	0.00629	0.0348	CbGeAlD
Aclidinium—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00627	0.00766	CbGpPWpGaD
Aclidinium—BCHE—central nervous system—Gilles de la Tourette syndrome	0.00606	0.0335	CbGeAlD
Aclidinium—CHRM3—brain—Gilles de la Tourette syndrome	0.00589	0.0326	CbGeAlD
Aclidinium—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00528	0.00645	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00523	0.00639	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00513	0.00626	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00508	0.0062	CbGpPWpGaD
Aclidinium—BCHE—brain—Gilles de la Tourette syndrome	0.00481	0.0266	CbGeAlD
Aclidinium—CHRM4—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00368	0.00449	CbGpPWpGaD
Aclidinium—CHRM4—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00357	0.00436	CbGpPWpGaD
Aclidinium—CHRM4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00342	0.00417	CbGpPWpGaD
Aclidinium—BCHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00337	0.00411	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00335	0.00409	CbGpPWpGaD
Aclidinium—CHRM4—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00333	0.00406	CbGpPWpGaD
Aclidinium—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00332	0.00405	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00331	0.00405	CbGpPWpGaD
Aclidinium—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00327	0.00399	CbGpPWpGaD
Aclidinium—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00318	0.00388	CbGpPWpGaD
Aclidinium—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00309	0.00377	CbGpPWpGaD
Aclidinium—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00296	0.00361	CbGpPWpGaD
Aclidinium—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00293	0.00357	CbGpPWpGaD
Aclidinium—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00284	0.00347	CbGpPWpGaD
Aclidinium—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00281	0.00343	CbGpPWpGaD
Aclidinium—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0028	0.00342	CbGpPWpGaD
Aclidinium—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00273	0.00333	CbGpPWpGaD
Aclidinium—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00272	0.00332	CbGpPWpGaD
Aclidinium—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00268	0.00327	CbGpPWpGaD
Aclidinium—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00265	0.00323	CbGpPWpGaD
Aclidinium—BCHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00258	0.00315	CbGpPWpGaD
Aclidinium—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00254	0.0031	CbGpPWpGaD
Aclidinium—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00253	0.00309	CbGpPWpGaD
Aclidinium—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00245	0.00299	CbGpPWpGaD
Aclidinium—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.0024	0.00293	CbGpPWpGaD
Aclidinium—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00238	0.0029	CbGpPWpGaD
Aclidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0023	0.00281	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0023	0.0028	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00227	0.00277	CbGpPWpGaD
Aclidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00224	0.00273	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00223	0.00272	CbGpPWpGaD
Aclidinium—CHRM4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00223	0.00272	CbGpPWpGaD
Aclidinium—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00222	0.0027	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00221	0.00269	CbGpPWpGaD
Aclidinium—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00216	0.00264	CbGpPWpGaD
Aclidinium—CHRM4—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00216	0.00264	CbGpPWpGaD
Aclidinium—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00215	0.00263	CbGpPWpGaD
Aclidinium—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00213	0.0026	CbGpPWpGaD
Aclidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00208	0.00254	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00208	0.00253	CbGpPWpGaD
Aclidinium—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00207	0.00253	CbGpPWpGaD
Aclidinium—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00207	0.00253	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00206	0.00251	CbGpPWpGaD
Aclidinium—CHRM4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00202	0.00246	CbGpPWpGaD
Aclidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00197	0.00241	CbGpPWpGaD
Aclidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00197	0.0024	CbGpPWpGaD
Aclidinium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00195	0.00238	CbGpPWpGaD
Aclidinium—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00193	0.00236	CbGpPWpGaD
Aclidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00192	0.00234	CbGpPWpGaD
Aclidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00191	0.00233	CbGpPWpGaD
Aclidinium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00189	0.00231	CbGpPWpGaD
Aclidinium—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00189	0.0023	CbGpPWpGaD
Aclidinium—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00188	0.0023	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.00187	0.00228	CbGpPWpGaD
Aclidinium—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00185	0.00226	CbGpPWpGaD
Aclidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00178	0.00218	CbGpPWpGaD
Aclidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00178	0.00217	CbGpPWpGaD
Aclidinium—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00177	0.00217	CbGpPWpGaD
Aclidinium—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00176	0.00215	CbGpPWpGaD
Aclidinium—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00169	0.00206	CbGpPWpGaD
Aclidinium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00168	0.00205	CbGpPWpGaD
Aclidinium—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0015	0.00183	CbGpPWpGaD
Aclidinium—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0015	0.00183	CbGpPWpGaD
Aclidinium—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00148	0.00181	CbGpPWpGaD
Aclidinium—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00146	0.00178	CbGpPWpGaD
Aclidinium—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00146	0.00178	CbGpPWpGaD
Aclidinium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00145	0.00177	CbGpPWpGaD
Aclidinium—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00145	0.00177	CbGpPWpGaD
Aclidinium—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00144	0.00176	CbGpPWpGaD
Aclidinium—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00144	0.00176	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00144	0.00175	CbGpPWpGaD
Aclidinium—CHRM4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00141	0.00172	CbGpPWpGaD
Aclidinium—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00136	0.00166	CbGpPWpGaD
Aclidinium—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00135	0.00165	CbGpPWpGaD
Aclidinium—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00135	0.00165	CbGpPWpGaD
Aclidinium—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00134	0.00164	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00126	0.00154	CbGpPWpGaD
Aclidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00125	0.00153	CbGpPWpGaD
Aclidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00125	0.00152	CbGpPWpGaD
Aclidinium—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00123	0.00151	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00122	0.00149	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00121	0.00147	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00117	0.00143	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00114	0.0014	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00114	0.00139	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00111	0.00136	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0011	0.00134	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00109	0.00133	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00106	0.0013	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00103	0.00126	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00099	0.00121	CbGpPWpGaD
Aclidinium—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000952	0.00116	CbGpPWpGaD
Aclidinium—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000949	0.00116	CbGpPWpGaD
Aclidinium—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000939	0.00115	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000849	0.00104	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000846	0.00103	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000838	0.00102	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000824	0.00101	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000822	0.001	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000814	0.000993	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000798	0.000974	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000771	0.000941	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000769	0.000938	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000768	0.000937	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000765	0.000934	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000764	0.000932	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000761	0.000929	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000758	0.000925	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000749	0.000914	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000746	0.000911	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000739	0.000902	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000724	0.000884	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000697	0.000851	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000695	0.000848	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000694	0.000847	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000688	0.00084	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000676	0.000825	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000656	0.000801	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000647	0.00079	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000628	0.000767	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000611	0.000746	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000585	0.000714	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000538	0.000656	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000536	0.000654	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000531	0.000648	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000488	0.000596	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000487	0.000594	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000482	0.000588	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000455	0.000556	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000454	0.000554	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00045	0.000549	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000442	0.00054	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000441	0.000538	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000437	0.000533	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000428	0.000522	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000412	0.000503	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000411	0.000501	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00041	0.0005	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000407	0.000496	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000289	0.000352	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000288	0.000351	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000285	0.000348	CbGpPWpGaD
